Crossmark

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

Crossref DOI link: https://doi.org/10.1186/s12885-018-4277-x

Published Online: 2018-03-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Yan

Zhang, Shijia

Wu, Fengying

Zhao, Jing

Li, Xuefei

Zhao, Chao

Ren, Shengxiang

Zhou, Caicun
License Information

Text and Data Mining valid from 2018-03-27
More Information

Article History

Received: 1 June 2017

Accepted: 21 March 2018

First Online: 27 March 2018

Ethics approval and consent to participate

: The study protocol was approved by the Ethical Review Committee of the Shanghai Pulmonary Hospital(No.K16–223-1) and informed consent was obtained from all individual participants included in the study.

: Not applicable.

: No potential conflicts of interest were disclosed.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.